Forest Laboratories, Inc. Reports Fiscal Year 2009 Fourth Quarter Reported EPS of $0.31 Including $0.45 Per Share Charge Related to the Ongoing United States Attorney's Office Inv... (tive tax rate for fiscal 2010 of approxi...)

HOME >> MEDICINE >> NEWS

Forest Laboratories, Inc. Reports Fiscal Year 2009 Fourth Quarter Reported EPS of $0.31 Including $0.45 Per Share Charge Related to the Ongoing United States Attorney's Office Investigation

Date:4/21/2009

tive tax rate for fiscal 2010 of approximately 21.5%

* Diluted shares outstanding will average approximately 303,000,000 for the fiscal year ending March 31, 2010.

Howard Solomon, Chairman and Chief Executive Officer of Forest, said: "Fiscal 2009 was a year of solid performance from our key promoted products, including a stronger than anticipated first year performance from Bystolic. During the year we were granted two important marketing approvals from the FDA. Firstly, Savella was approved for the management of fibromyalgia, following a first cycle review. Savella is a valuable new treatment option for patients with the chronic and often debilitating condition of fibromyalgia. Also, Lexapro received approval for the important additional indication for the acute and maintenance treatment of major depressive disorder in adolescents, 12 to 17 years of age. Further, we received a patent term extension for Namenda which extends its exclusivity to April, 2015. Along with the steady progress of our product pipeline, we were also very pleased to announce the addition of two late-stage products. We partnered with the Phenomix Corporation to develop and commercialize dutogliptin, for the treatment of Type 2 diabetes mellitus and with Pierre Fabre Medicament to develop and commercialize levomilnacipran for the treatment of depression.

In fiscal 2010, we will continue to advance our product development pipeline, which includes six products in Phase III development and two products currently in Phase II-b development that we expect to progress into Phase III later this year. Very shortly we will begin additional Phase III studies of aclidinium, for the treatment of COPD, to provide further support for higher and/or more frequent dosage regimens which we expect will significantly increase the potential clinical utility of this novel compound. In the coming months we expect to file a sNDA for Bystolic for the treatment
'/>"/>

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11
Related medicine news :

1. AUDIO from Medialink and Forest Pharmaceuticals: FDA Approves Lexapro for Major Depressive Disorder in Adolescents
2. Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Commercial Availability of Savella(TM)
3. AUDIO from Medialink and Forest Pharmaceuticals: FDA Approves Lexapro for Major Depressive Disorder in Adolescents
4. Forest Laboratories, Inc. Announces FDA Approval of Lexapro(R) for the Treatment of Major Depressive Disorder in Adolescents
5. German Federal Patent Court Invalidates Wake Forest NPWT Patents Licensed to KCI
6. Wake Forest Baptist and Rivulet Connect New Operating Rooms with Interactive Video
7. Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Revised Timing for Commercial Availability of Savella(TM)
8. Forest Laboratories, Inc. Provides Statement in Response to Complaint Filed by U.S. Government
9. United States Files Complaint Against Forest Laboratories for Allegedly Violating the False Claims Act
10. Old-Growth Forests Dying Off in U.S. West
11. Forest Laboratories, Inc. Reports Q309 Diluted Earnings Per Share of $0.62, Including $0.41 Per Share Charge for New Product Licensing Fees

Post Your Comments:

Forest Laboratories, Inc. Reports Fiscal Year 2009 Fourth Quarter Reported EPS of $0.31 Including $0.45 Per Share Charge Related to the Ongoing United States Attorney's Office Inv...(tive tax rate for fiscal 2010 of approxi...),Health